arrow
J

Jing Wang

md anderson cancer center
H指数:85
被引数:3.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction

CDK2抑制剂BLU-222通过p21/p27诱导与CDK4/6抑制剂在耐药性乳腺癌中的协同作用

2026-01-220
OAAI
CD47 blockade-driven necroptosis complements BCL-2 inhibition-driven apoptosis in lymphoid malignancies

CD47阻断驱动的坏死性凋亡补充了淋巴恶性肿瘤中BCL-2抑制驱动的凋亡

2026-01-030
OAAI
A 6 to 9-month oral regimen for rifampicin-resistant tuberculosis: a randomised open-label non-inferiority trial in China

利福平耐药结核病的6至9个月口服方案:一项在中国进行的随机开放标签非劣效性试验

2025-11-240
PRE
Acquired Resistance during Short-Course Treatment for Rifampicin-Resistant Tuberculosis

利福平耐药结核病短疗程治疗期间的获得性耐药

2025-11-040
OAAI
Genomic and Epigenomic Signatures Can Distinguish Aggressive Chromophobe Renal Cell Carcinoma from Indolent Renal Oncocytic Tumors in Clinical-grade Samples

基因组与表观基因组特征能够区分临床级样本中侵袭性的嗜酸性肾细胞癌与惰性的肾源性肿瘤。

2025-11-040
PRE
DIRAS3-derived cyclic peptides disrupt KRAS-RAF interaction and KRAS nanoclustering, suppressing KRAS-driven pancreatic and ovarian tumors

DIRAS3衍生的环状肽破坏KRAS-RAF相互作用和KRAS纳米聚集,抑制KRAS驱动的胰腺和卵巢肿瘤

2025-10-040
OAAI
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy

癌症诱导的神经损伤促进抗PD-1疗法的耐药性

Nature
IF48.5
2025-08-200
OA
A Short, All-oral Regimen for Preextensively Drug-resistant Tuberculosis: A Multicenter Open-label Single-arm Study

一种短程全口服方案用于广泛耐药肺结核的预防:一项多中心开放标签单臂研究

2025-08-010
OAAI
PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models (vol 67, pg 1262, 2024)

PROTACs靶向BRM(SMARCA2)可在体内实现对BRG1(SMARCA4)的选择性降解,并在BRG1突变异种移植肿瘤模型中表现出活性(vol 67, pg 1262, 2024)

2025-05-210
PRE